A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS

Multiple Sclerosis Journal

Volumn 20, Issue 6, 2014, Pages 717-725

  Ramo Tello, C ^a   Grau Lopez L ^a   Tintore M ^b   Rovira, A ^b   Ramio I Torrenta L ^c   Brieva, L ^d   Cano, A ^e   Carmona, O ^f   Saiz, A ^g   Torres, F ^g   Giner, P ^a   Nos, C ^b   Massuet, A ^a   Montalban X ^b   Martinez Caceres E ^a   Costa, J ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c Department of Gastroenterology   (Spain)

^d HOSPITAL ARNAU DE VILANOVA   (Spain)

^e HOSPITAL DE MATARÓ   (Spain)

^f HOSPITAL DE FIGUERES   (Spain)

^g Hospital Clínic i Provincial ^*  (Spain)

Author keywords

Methylprednisolone; multiple sclerosis; relapses

Indexed keywords

GADOLINIUM; METHYLPREDNISOLONE; PLACEBO;

ABDOMINAL PAIN; ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EMOTIONAL DISORDER; EUPHORIA; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FEMALE; HEART PALPITATION; HUMAN; INSOMNIA; MALE; METALLIC TASTE; MOOD DISORDER; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NAUSEA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHASE 4 CLINICAL TRIAL; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; STOMACH PAIN; AGED; CLINICAL TRIAL; DIAGNOSTIC USE; DISABILITY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RECURRENT DISEASE; TREATMENT OUTCOME; ANXIETY; HEADACHE; SPAIN; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADULT; AGED; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 84899077618     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513508835     Document Type: Article

References (34)

1. Devins GM, Edworthy SM, Seland TP, et al. Differences in illness intrusiveness across rheumatoid arthritis, end-stage renal disease, and multiple sclerosis. J Nerv Ment Dis. 1993 ; 181: 377-381
2. Dalos NP, Rabins PV, Brooks BR, et al. Disease activity and emotional state in multiple sclerosis. Ann Neurol. 1983 ; 13: 573-577
3. Barnes D, Hughes RA, Morris RW, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet. 1997 ; 349: 902-906
4. Durelli L, Cocito D, Riccio A, et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: Clinical-immunologic correlations. Neurology. 1986 ; 36: 238-243
5. Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry. 1987 ; 50: 511-516
6. Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev. 2000 ; 4 :
7. Leary SM, Porter B, Thompson AJ. Multiple sclerosis: Diagnosis and the management of acute relapses. Postgrad Med J. 2005 ; 81: 302-308
8. Barkhof F, Hommes OR, Scheltens P, et al. Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology. 1991 ; 41: 1219-1222
9. Zivadinov R, Zorzon M, De Masi R, et al. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis. J Neurol Sci. 2008 ; 267: 28-35
10. Hoogervorst EL, Polman CH, Barkhof F. Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Mult Scler. 2002 ; 8: 415-419
11. Martinelli V, Rocca MA, Annovazzi P, et al. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. Neurology. 2009 ; 73: 1842-1848
12. Sellebjerg F, Barnes D, Filippini G, et al. EFNS guideline on treatment of multiple sclerosis relapses: Report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol. 2005 ; 12: 939-946
13. Tremlett HL, Luscombe DK, Wiles CM. Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom. J Neurol Neurosurg Psychiatry. 1998 ; 65: 362-365
14. Morrow SA, Metz LM, Kremenchutzky M. High dose oral steroids commonly used to treat relapses in Canadian MS clinics. Can J Neurol Sci. 2009 ; 36: 213-215
15. Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997 ; 15: 110-115
16. Borner MM, Schoffski P, de Wit R, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer. Eur J Cancer. 2002 ; 38: 349-358
17. Morrow SA, McEwan L, Alikhani K, et al. MS patients report excellent compliance with oral prednisone for acute relapses. Can J Neurol Sci. 2012 ; 39: 352-354
18. MetzLMHarrisCJMooreA. MS patients' choice of oral rather than IV steroid therapy results in savings to health care system. Int J MS Care2000March (cited 2010 Sept) www.mscare.org.
19. Metz LM, Sabuda D, Hilsden RJ, et al. Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis. Neurology. 1999 ; 53: 2093-2096
20. O'Brien JA, Ward AJ, Patrick AR, et al. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res. 2003 ; 3: 17
21. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005 ; 58: 840-846
22. Nos C, Sastre-Garriga J, Borràs C, et al. Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis. Mult Scler. 2004 ; 10: 413-416
23. Rovira A, Tintoré M, Alvarez-Cermeño JC, et al. Recommendations for using and interpreting magnetic resonance imaging in multiple sclerosis. Neurologia. 2010 ; 25: 248-265
24. Hollander M, Wolfe DA Nonparametric statistical methods. New York: John Wiley & Sons ; 1973 :
25. Sharrack B, Hughes RA, Morris RW, et al. The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis. J Neurol Sci. 2000 ; 173: 73-77
26. Smith MD, Ahern MJ, Roberts-Thomson PJ. Pulse steroid therapy in rheumatoid arthritis: Can equivalent doses of oral prednisolone give similar clinical results to intravenous methylprednisolone?. Ann Rheum Dis. 1988 ; 47: 28-33
27. Ratto D, Alfaro C, Sipsey J, et al. Are intravenous corticosteroids required in status asthmaticus?. JAMA. 1988 ; 260: 527-529
28. Alam SM, Kyriakides T, Lawden M, et al. Methylprednisolone in multiple sclerosis: A comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry. 1993 ; 56: 1219-1220
29. Beck RW, Cleary PA, Anderson MM, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992 ; 326: 581-588
30. Alejandro PM, Castañón Gonzalez JA, Miranda Ruiz R, et al. Comparative treatment of acute optic neuritis with "boluses" of intravenous methylprednisolone or oral prednisone. Gac Med Mex. 1994 ; 130: 227-230
31. Burton JM, O'Connor PW, Hohol M, et al. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev. 2009 ; 3 :
32. Morrow SA, Stoian CA, Dmitrovic J, et al. The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology. 2004 ; 63: 1079-1080
33. Perumal JS, Caon C, Hreha S, et al. Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis. Eur J Neurol. 2008 ; 15: 677-680
34. Miller DH, Thompson AJ, Morrissey SP, et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry. 1992 ; 55: 450-453